ArticleExperimental and therapeutic medicine2021
Curcumin inhibits the viability, migration and invasion of papillary thyroid cancer cells by regulating the miR-301a-3p/STAT3 axis.
Article in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Mechanistic and Clinical Perspectives on Traditional Chinese Medicine in Thyroid Cancer Management.Biomolecules & therapeutics · 2026Review
- Ferroptosis induction by curcumin through regulating the expression of glutathione peroxidase 4 in papillary thyroid carcinoma.Journal of molecular histology · 2026Article
- Transcriptional factor ZMYM3 promotes hepatocellular carcinoma metastasis by upregulating CTTN and inducing invadopodia formation.Cell death & disease · 2026Article
- Curcumin as a Multi-Target Bioactive Molecule: Mechanistic Insights and Translational Perspectives.International journal of molecular sciences · 2026Review
- Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer.International journal of molecular sciences · 2025Review
- Targeting the Purinergic Axis with Phenolic Compounds to Disrupt the Oxidative-Inflammatory Cycle in Thyroid Cancer.International journal of molecular sciences · 2025Review
- Exploring miR-301a-3p and osteosarcoma: from expression differences to mechanism of action.Discover oncology · 2025Article
- Fmoc-FF Nanogel-Mediated Delivery of Doxorubicin and Curcumin in Thyroid Cancer Cells.Pharmaceutics · 2025Article
- A novel approach to regulate glucose uptake in an anaplastic thyroid cancer cell line.Endocrine connections · 2025Article
- Promising Approaches in Plant-Based Therapies for Thyroid Cancer: An Overview of In Vitro, In Vivo, and Clinical Trial Studies.International journal of molecular sciences · 2024Review
- Turmeric Inhibits MDA-MB-231 Cancer Cell Proliferation, Altering miR-638-5p and Its Potential Targets.European journal of breast health · 2024Article
- Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?Frontiers in oncology · 2024Review
- The Role of MMP-9 and MMP-9 Inhibition in Different Types of Thyroid Carcinoma.Molecules (Basel, Switzerland) · 2023Review
- Mediterranean Diet and Thyroid: An Interesting Alliance.Nutrients · 2022Review
- Effects and Mechanisms of Curcumin for the Prevention and Management of Cancers: An Updated Review.Antioxidants (Basel, Switzerland) · 2022Review
- A Comprehensive Review on the Benefits and Problems of Curcumin with Respect to Human Health.Molecules (Basel, Switzerland) · 2022Review
- Targeting the Cancer Stem Cells in Endocrine Cancers with Phytochemicals.Current topics in medicinal chemistry · 2022Article
- Modern aspects of the use of natural polyphenols in tumor prevention and therapy.Frontiers in cell and developmental biology · 2022Review
- Curcumin and its nano-formulations: Defining triple-negative breast cancer targets through network pharmacology, molecular docking, and experimental verification.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer is one of the most common malignant tumors, and the mortality rate associated with thyroid cancer has been increasing annually. Curcumin has been reported to exert an antitumor effect on papillary thyroid cancer (PTC), and the identification of additional mechanisms underlying the anticancer effect of curcumin on PTC requires further investigation. The present study aimed to explore the effects of curcumin on the viability, migration and invasion of PTC cells. TPC-1 cells were incubated with different concentrations of curcumin, and then, cell viability, migration and invasion, and wound healing were examined by CCK-8, Transwell and wound healing assays, respectively. Subsequently, microRNA (miR)-301a-3p mimics, miR-301a-3p inhibitors and signal transducer and activator of transcription (STAT)3 overexpression vector were transfected into TPC-1 cells, and cell viability, migration, and invasion were reassessed in these transfected cells. Matrix metallopeptidase (MMP)-2, MMP-9, epithelial-mesenchymal transition (EMT)-related markers, and Janus kinase (JAK)/STAT signaling pathway components were assessed by western blot analysis. Curcumin significantly inhibited cell viability, migration and invasion and downregulated MMP-2, MMP-9 and EMT marker expression. Additionally, curcumin decreased STAT3 expression by upregulating miR-301a-3p expression, and the inhibition of miR-301a-3p and the overexpression of STAT3 reversed the effects of curcumin on cell viability, migration and invasion, and MMP-2, MMP-9 and EMT marker expression in TPC-1 cells. Furthermore, curcumin suppressed the JAK/STAT signaling pathway through the miR-301a-3p/STAT3 axis. The data of the present study indicated that curcumin could inhibit the viability, migration and invasion of TPC-1 cells by regulating the miR-301a-3p/STAT3 axis. These findings may provide a possible strategy for the clinical treatment of PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.